![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Tuesday, November 18, 2014 4:08:31 PM
Means more crappy financing deals and dilution to look forward too. Almost every holding AMBS has is 3-4+ years out.
Add this to the spin out, the reverse split, the uplist, etc. Gerald has promised just about every holy grail in the book (Minus the R/S) and still nothing has come from it.
Even if they split it up to the NASDAQ, they won't be able to keep it there without significant Lympro revenues.
And If they spin out diagnostics, the R&D entity will have no revenues to speak of and become a huge dilution vehicle.
After today, there's a lot more riding on Lympro revenues than there was previously.
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM